Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug;39(11):2159-2163.
doi: 10.1038/s41433-025-03813-2. Epub 2025 May 3.

Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study)

Sahar Avadzadeh  1 , Ashish Sharma  2 , Mohammad Mehdi Parvaresh  3 , Khalil Ghasemi Falavarjani  3   4 ; International Retina Biosimilar Study Group (Inter BIOS Group)
Collaborators, Affiliations
Observational Study

Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study)

Sahar Avadzadeh et al. Eye (Lond). 2025 Aug.

Abstract

Purpose: To evaluate the early real-world clinical outcomes regarding safety and efficacy after administering the aflibercept 2 mg biosimilar (Tyalia, Cinnagen, Tehran, Iran).

Methods: A retrospective, uncontrolled observational study was conducted with a total of 499 Tyalia injections given in 189 eyes of 148 patients for variable indications. All patients were treated with at least one intravitreal injection of Tyalia 2 mg; 102 eyes with neovascular age-related macular degeneration (n-AMD), 67 eyes with diabetic macular oedema (DMO), and 20 eyes with retinal vein occlusion (RVO) associated with macular oedema were included in the analysis.

Results: The mean central subfield thickness (CST) of the overall group improved from baseline to the last follow-up from 408.8 ± 155.1 µ to 353.4 ± 142.4 µ (p < 0.001). Best corrected visual acuity was found to be stable in the total cohort. The total number of adverse events (AEs) was (0.4%).

Conclusions: The preliminary real-world data from this limited early series suggest that Tyalia appears to have similar clinical efficacy and safety as aflibercept 2 mg innovator across the approved indications. However, long-term data with a larger population are needed to further strengthen the findings of this study.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KGF: Consultant for CinnaGen. Ashish Sharma: Consultant for Bayer, Lupin, Novartis, Allergan, Roche and Intas. SA and MMP: None.

References

    1. Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294. - PMC - PubMed
    1. Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti-vascular endothelial growth factor biosimilars in ophthalmology. Retina 2022;42:2243–50. - PMC - PubMed
    1. Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68:2143–7. - PMC - PubMed
    1. Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for retinal diseases: an update. Am J Ophthalmol. 2021;224:36–42. - PubMed
    1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023;37:200–2. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources